미허가 긴급도입의약품으로 교과서, 관련 학회의견 및 임상논문 등을 참조하여 식품의약품안전청장이 인정한 범위 내에서 투여 시 요양급여를 인정함.
■ 관련문헌 등
· Katzung’s Basic & Clinical Pharmacology, 16e
· Goldfrank's Toxicologic Emergencies, 11e
· Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14e
· Glahn et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group(EMHG)
· Hopkins et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021; 76(5): 655？664
· Wappler F. S1-Leitlinie maligne Hyperthermie: update 2018. Der Anaesthesist. 2018;67(7):529？532
· Malignant Hyperthermia Association of the United States(MHAUS)
· Toyota Y et al, Rapid Dantrolene Administration with Body Temperature Monitoring Is Associated with Decreased Mortality in Japanese Malignant Hyperthermia Events. Biomed Res Int. 2023;2023:8340209
· Sanchez-Molina et al, Malignant Hyperthermia Syndrome: A Clinical Case Report, EJIFCC. 2021;32(2):286？291
· Lee at al. A case of malignant hyperthermia during anesthesia induction with sevoflurane -A case report Korean J Anesthesiol 2010; 59: S6-S8
· G Islander. Dantrolene in the treatment of malignant hyperthermia: a case report, BMC Anesthesiology, 2014 Aug 18;14(Suppl 1):A7